MARKET

IDYA

IDYA

Ideaya Biosciences
NASDAQ
32.16
-0.01
-0.03%
Opening 14:19 02/09 EST
OPEN
32.12
PREV CLOSE
32.17
HIGH
32.64
LOW
31.81
VOLUME
252.25K
TURNOVER
--
52 WEEK HIGH
39.28
52 WEEK LOW
13.45
MARKET CAP
2.82B
P/E (TTM)
-17.3407
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IDYA last week (0202-0206)?
Weekly Report · 17h ago
IDEAYA Biosciences Joins Virtual Oncology Leadership Summit and Hosts Investor Fireside Chat
Reuters · 02/02 11:00
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
PR Newswire · 02/02 11:00
Weekly Report: what happened at IDYA last week (0126-0130)?
Weekly Report · 02/02 09:06
Is IDEAYA Biosciences (IDYA) Pricing Reflect Its DCF Upside After Recent Share Pullback
Simply Wall St · 01/31 17:34
IDEAYA Biosciences Grants Stock Options to New Employee Under Inducement Plan
Reuters · 01/30 11:00
IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/30 11:00
Weekly Report: what happened at IDYA last week (0119-0123)?
Weekly Report · 01/26 09:06
More
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Webull offers Ideaya Biosciences Inc stock information, including NASDAQ: IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.